- Home
- ROIV
as 03-25-2025 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | HAMILTON HM11 |
| Market Cap: | 8.4B | IPO Year: | N/A |
| Target Price: | $18.08 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.93 - $13.06 | Next Earning Date: | 02-10-2025 |
| Revenue: | $122,585,000 | Revenue Growth: | 140.04% |
| Revenue Growth (this year): | -22.88% | Revenue Growth (next year): | -70.25% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & COO | Mar 20 '25 | Sell | $10.94 | 750,000 | $8,190,725.28 | 959,457 | |
| Venker Eric | ROIV | President & COO | Feb 20 '25 | Sell | $10.65 | 100,000 | $1,065,000.00 | 959,457 | |
| Kumar Rakhi | ROIV | Chief Accounting Officer | Feb 13 '25 | Sell | $10.43 | 227,500 | $2,372,825.00 | 163,264 | |
| Venker Eric | ROIV | President & COO | Feb 12 '25 | Sell | $10.48 | 435,425 | $4,561,040.74 | 959,457 | |
| Venker Eric | ROIV | President & COO | Jan 20 '25 | Sell | $11.28 | 100,000 | $1,128,000.00 | 959,457 | |
| Venker Eric | ROIV | President & COO | Dec 27 '24 | Sell | $11.68 | 354,604 | $4,141,662.16 | 959,457 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
Investor's Business Daily
7 days ago
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Investor's Business Daily
7 days ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
GlobeNewswire
7 days ago
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
GlobeNewswire
8 days ago
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
GlobeNewswire
23 days ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
GlobeNewswire
a month ago
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board
TipRanks
a month ago
Roivant Sciences price target lowered to $12 from $13 at BofA
Simply Wall St.
a month ago
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.